Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections

Journal of Chemotherapy

Volumn 29, Issue 1, 2017, Pages 25-29

  Trad, Mohamad Ali ^a,b   Zhong, Lihua H ^c   Llorin, Ryan M ^c   Tan, Shire Yang ^a   Chan, Monica ^c   Archuleta, Sophia ^a   Sulaiman, Zuraidah ^a   Tam, Vincent H ^d   Lye, David C ^b,c   Fisher, Dale A ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

Complicated urinary tract infections (cUTIs); Ertapenem; Multi drug resistant organisms; Outpatient parenteral antimicrobial therapy

Indexed keywords

CREATININE; ERTAPENEM; ANTIINFECTIVE AGENT; BETA LACTAM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; CONTROLLED STUDY; ESCHERICHIA COLI; ETHNICITY; FEMALE; HEADACHE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; OBSERVATIONAL STUDY; OPEN STUDY; PROSPECTIVE STUDY; RASH; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTION; VOMITING; AMBULATORY CARE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; URINARY TRACT INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84978468669     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1080/1120009X.2016.1158937     Document Type: Article

References (16)

1. Nicolle LE, Evans G, Laverdieve M, Phillips P, Quan C, Rotstein C. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16:349–60.
2. Hooton TM. Urinary tract infections in adults. N Engl J Med. 2012;366:1028–37.10.1056/NEJMcp1104429
3. Oteoa J, Perez-Vazquez M, Campos J. Extended-spectrum B-lactamase producing Escherichia coli:changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–6.10.1097/QCO.0b013e3283398dc1
4. Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell EB, et al. Ertapenem susceptibility of extended-spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob. 2007;6:6–10.10.1186/1476-0711-6-6
5. Fong JJ, Rosé L, Radigan EA. Clinical outcomes with Ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing Gram-negative bacteria. Ann Pharmacother. 2012;46:347–52.10.1345/aph.1Q473
6. Zhou J, Sulaiman Z, Llorin R, Hee K-H, Lee L, Lye D, Fisher D, Tam V. Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. J Antimicrob Chemother. 2014;69:2517–2521.
7. Tomera KM, Burdmann EA, Reyna OG, Jiang Q, Wimmer WM, Woods GL, et al. Ertapenem versus Ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults:results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002;46:2895–2900.10.1128/AAC.46.9.2895-2900.2002
8. Bazaz R, Champan ALN, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tracet infections caused by extended-spectrum-B-lactamase-producing Gram-negative organisms. J Antimicrob Chemother. 2010;65:1510–13.10.1093/jac/dkq152
9. Song S, Kim C, Lim D. Clinical efficacy of Ertapenem for recurrent cystitis caused by multi-drug-resistant extended-spectrum B-lactamase-producing Eschericia coli in female outpatients. Korean J Urol. 2014;55:270–275.10.4111/kju.2014.55.4.270
10. Qureshi ZA, Syed A, Doi Y. Safety and efficacy of long-term outpatient ertapenem therapy. Antimicrob Agents Chemother. 2014;58:3437–40.10.1128/AAC.02721-14
11. Fisher DA, Kurup A, Lye D, Tambyah PA, Sulaiman Z, Poon EYH, Lee W, et al. Outpatient parenteral antibiotic therapy in Singapore. Int J Antimicrob Agents. 2006;28:545–550.10.1016/j.ijantimicag.2006.08.018
12. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. General guidelines for the evaluation of anti-infective drugs for the treatment of urinary tract infection. Clin Infect Dis. 1992;15(Supplement 1):S216–S227.10.1093/clind/15.Supplement_1.S216
13. Lye DC, Wijaya L, Chan J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum beta-lactamase producing multidrug-resistant gram-negative bacteraemia. Ann Acad Med Sing. 2008;37:831–4.
14. Wu UI, Chen WC, Yang CS, Wang JL, Hu FC, Chang SC, et al. Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli:a propensity score analysis. Int J Infect Dis. 2012;16:e47–e52.10.1016/j.ijid.2011.09.019
15. Collins V, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, et al. Efficacy of Ertapenem for treatment of blood stream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56:2173–7.10.1128/AAC.05913-11
16. Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011;43:339–343.10.3109/00365548.2011.553241